Camber Spine Technologies, LLC — TTAB Proceedings
Camber Spine Technologies, LLC is a party to 2 TTAB proceedings.
Proceedings
- Proceeding 97108884 — Extensions of Time to Oppose, Terminated (filed 2022-03-02) against Biogena Naturprodukte GmbH & Co KG as defendant
- Proceeding 90614703 — Extensions of Time to Oppose, Terminated (filed 2021-10-15) against Bioverativ Therapeutics Inc. as defendant
Marks in These TTAB Matters
Recent Live Filings
- INFILL — Registered, filed 2023-12-14
- ALCANTARA — Pending, filed 2023-06-29
- C CAMBER SPINE LIFE UPRIGHT — Registered, filed 2023-01-30
- CAMBER SPINE — Registered, filed 2023-01-30
- CAMBER — Registered, filed 2023-01-30
- COVERIS — Pending, filed 2022-12-06
- BIA-GEN — Registered, filed 2021-11-04
- ALTIVO — Registered, filed 2021-04-28
- VARIANT ACCESS SYSTEM — Registered, filed 2021-02-04
- VARIANT — Registered, filed 2021-01-18
- BLADE TO BLADE — Registered, filed 2020-08-04
- LIFE UPRIGHT — Registered, filed 2018-06-17
- SPIRA — Registered, filed 2017-12-13
- SURFACE BY DESIGN — Registered, filed 2017-12-13
- ENZA — Registered, filed 2017-10-08
Common TTAB Counterparties
- Biogena Naturprodukte GmbH & Co KG — 1 proceedings
- Bioverativ Therapeutics Inc. — 1 proceedings
Recent TTAB Timeline
- 2022-06-01: 97108884 — EXTENSION OF TIME GRANTED involving Biogena Naturprodukte GmbH & Co KG
- 2022-06-01: 97108884 — FINAL 60-DAY REQUEST TO EXT TIME TO OPPOSE involving Biogena Naturprodukte GmbH & Co KG
- 2022-03-03: 97108884 — EXTENSION OF TIME GRANTED involving Biogena Naturprodukte GmbH & Co KG
- 2022-03-03: 97108884 — FIRST 90-DAY REQUEST TO EXT TIME TO OPPOSE involving Biogena Naturprodukte GmbH & Co KG
- 2022-03-02: 97108884 — EXTENSION OF TIME GRANTED involving Biogena Naturprodukte GmbH & Co KG
- 2022-03-02: 97108884 — FIRST 90-DAY REQUEST TO EXT TIME TO OPPOSE involving Biogena Naturprodukte GmbH & Co KG
- 2021-10-15: 90614703 — EXTENSION OF TIME GRANTED involving Bioverativ Therapeutics Inc.
- 2021-10-15: 90614703 — FIRST 90-DAY REQUEST TO EXT TIME TO OPPOSE involving Bioverativ Therapeutics Inc.